联系我们中文English
兼职导师 当前所在位置:首页 >> 师资队伍 >> 教师名录 >> 兼职导师

上海交大生物医学工程-上海市肿瘤所联合培养基地导师

时间:2016-01-25

    : 段友容

    : 研究员

通讯地址:上海市斜土路220025

办公电话:021-64437139

Website www.shsci.org

E-mailyrduan@shsci.org

 

受教育经历:

2002/06-2004/05 四川大学,华西药学院博士后流动站,博士后

1999/09-2002/05 四川大学,国家生物材料工程研究中心,博士

1996/02-1999/08 四川大学,高分子材料学院,硕士

 

研究工作经历:

2010/10-至今   上海交通大学,医学院附属仁济医院上海市肿瘤研究所癌基因及相关基因国家重点实验室,研究员

2008/12-2010/9 上海市肿瘤研究所,癌基因及相关基因国家重点实验室,研究员

2005/7-2008/11上海市肿瘤研究所,癌基因及相关基因国家重点实验室,副教授

2004/05-2005/08  东华大学,材料学院纤维改性国家重点实验室,副教授

2003/07-2004/04 四川大学,华西药学院博士后流动站,副教授

 

主要研究方向:

?逆转或降低肿瘤耐药性药物递送系统设计及应用

?肿瘤靶向药物(基因)载体设计以及抗肿瘤给药系统的构建(缓控释)

 

申请或者授权专利情况(近5年):

(1)7项中国授权专利。

(2)申请2项美国专利、1项日本专利。

(3)申请26项中国专利。

 

承担的主要项目:

◆ 国家自然科学基金(面上项目)(No.81272568),两相释药降低乳腺癌细胞耐药靶向给药系统的研究

◆ 国家自然科学基金(青年基金)(No.81101738),负载siRNA-EGFR的mPEG-PLGA -PLL-cRGD纳米递送系统的构建及其抗乳腺癌疗效的研究

◆ 国家自然科学基金(青年基金)(No.81301973),多重靶向酶响应型载Au-Pt(IV)纳米载体的构建及对卵巢癌的治疗研究

◆ 国家重大科学研究计划项目(973项目)(No.2010CB529902),非病毒基因新型载体材料的研究

◆ 上海市科委纳米中心项目(No. 1052nm05900),PLGA-PLL核靶向纳米给药系统构建及肝癌治疗研究

◆ 上海市科委医学引导项目114119a3300,新型磷酸钙/磷脂-PEG复合靶向肺癌给药系统构建

◆ 上海交通大学医工交叉学科YG2010MS71,多层金纳米球壳的光学特性及其在肿瘤热疗和成像中的应用

◆ 上海交通大学医工交叉学科YG2011MS25,直肠癌诊断与治疗并行系统中集成化纳米探针的构建

 

招生要求:医学、药学、材料学、生物学等相关专业背景

 

期刊论文:(通讯作者发表的科研论文)

  1. Peifeng Liu, Yanming Sun, Qi Wang, Ying Sun, He Li, Yourong Duan*. Intracellular trafficking and cellular uptake mechanism of mPEG-PLGA-PLL and mPEG-PLGA-PLL-Gal nanoparticles for targeted delivery to hepatomas. Biomaterials.,35:760-770,2014

  2. Qiusheng Shi, Peifeng Liu, Ying Sun, Huiping Zhang, Jing Du, Fan Li, Lianfang Du, Yourong Duan*. siRNA Delivery Mediated by Copolymer Nanoparticles, Phospholipid Stabilized Sulphur Hexafluoride Microbubbles and Ultrasound. Journal of Biomedical Nanotechnology,10(9): 436-444. 2014.

  3. Qi Wang, Peifeng Liu, Ying Sun, Heng Wu, Xiaoyu Li, Yourong Duan* and Zhirong zhang. Pluronic-PAGA Polymeric Micelle-like Nanoparticles as Carrier for Drug Delivery. Journal of Nanoscience and Nanotechnology, 10(11):993-1003.2014

  1. Yunfei Wang, Peifeng Liu, Lihua Qiu, Ying Sun, Mingjie Zhu, Liying Gu, Wen Di, Yourong Duan*. Toxicity and therapy of cisplatin -loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials, 34: 4068-4077, 2013.

  2. Ying Sun, Xiaoyu Li, Xiaofei Liang, Zhiyong Wan and Yourong Duan*. Calcium Phosphate/Octadecyl-Quatemized Carboxymethyl Chitosan Nanoparticles: An Efficient and Promising Carrier for Gene Transfection. Journal of Nanoscience and Nanotechnology, 13: 5260-5266,2013

  3. Liubin Qin, Ying Sun, Peifeng Liu, Qi Wang, Baosan Han and Yourong Duan*. F127/Calcium phosphate hybrid nanoparticles: a promising vector for improving siRNA delivery and gene silencing. Journal of Biomaterials Science, Polymer Edition., 24(15): 1757-1766.,2013.

  4. Yiyi Wang, Peifeng Liu, Jing Du, Ying Sun, Fenghua Li and Yourong Duan*. Targeted siRNA delivery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer. Journal of Biomaterials Science, Polymer Edition., 24(10): 1219-1232, 2013.

  5. Yunman Wang, Ying Sun, Hao Wang, Peifeng Liu, Wen Peng and Yourong Duan*. Synthesis of low-molecular weight protein (LMWP) lysozyme–curcumin conjugates for kidney drug targeting. Journal of Biomaterials Science, Polymer Edition, 24(11): 1360-1367, 2013.

  6. Yunhua Li, Qiusheng Shi, Jing Du, Lifang Jin, Lianfang Du, Peifeng Liu, Yourong Duan*. Targeted delivery of biodegradable nanoparticles with ultrasound-targeted microbubble destruction-mediated hVEGF-siRNA transfection in human PC-3 cells in vitro. International Journal of Molecular Medicine, 31: 163-171,2013.

  7. Yunfei Wang, Peifeng Liu, Yourong Duan, Xia Yin, Qi Wang, Xiaofei Liu,Xinran Wang, Jinhua Zhou, Wenwen Wang, Lihua Qiu, Wen Di. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer. Biomaterials, http://dx.doi.org /10.1016/ j. biomaterials. 2013. 09.062,2014.

  8. Ying Sun, Liubin Qin, Dejun Liu, Changhong Liu, Yongwei Sun and Yourong Duan*.. Fast Detection of Alpha-Fetoprotein-L3 Using Lens Culinaris Agglutinin Immobilized Gold Nanoparticles. Journal of Nanoscience and Nanotechnology. Accept 2013.

  9.  Qi Wang, Peifeng Liu, Ying Sun, Heng Wu, Xiaoyu Li, Yourong Duan*,Zhirong zhang. Pluronic-PAGA Polymeric Micelle-like Nanoparticles as Carrier for Drug Delivery. Journal of Nanoscience and Nanotechnology. 2013. doi:10.1166/jnn.2013.8666.2013

  10. Jun Zhang, Zhichao Ma, Peifeng Liu, Qin Ji, Jie Qi, Yourong Duan*. Antitumor Efficacy of Paclitaxel-Loaded Polylactide/Poly(ethylene glycol) Nanoparticles Combination with Exercise in Tumor-Bearing Mice. Journal of Nanoscience and Nanotechnology. doi:10.1166/jnn.2013.7201,2013.

 

 

李锦军,男,1964.1出生,博士/研究员/博导,上海交通大学附属仁济医院 上海市肿瘤研究所 癌基因及相关基因国家重点实验室 课题组长

联系方式:Tel: 021-64432140; E-mail: jjli@shsci.org

 

主要学习经历

1982.9-1986.7       甘肃农业大学兽医学,兽医专业   学士

1986.9-1989.7       延边大学农学院动物医学系,病理学专业 硕士

1993.4-1997.3       日本国立山口大学大学院,比较病理学专业    博士(PhD)

 

主要工作经历

1989.7-1990.7       延边大学农学院动物医学系    助教

1990.8-1997.5       延边大学农学院动物医学系    讲师

1997.6-1999.2       农业部国家兽医诊断中心 兽医师

1999.3-2000.11   上海市肿瘤研究所国家重点实验室       助研

2000.12-2003.6   上海市肿瘤研究所国家重点实验室       副研

2003.7-2005.11   上海市肿瘤研究所国家重点实验室   副研/课题组长/硕导

2005.12-现在        上海市肿瘤研究所国家重点实验室      研究员/课题组长/博导

 

主要研究领域

肿瘤干细胞靶向治疗、肿瘤耐药、肿瘤转移分子机制

 

 

重要科技奖项及荣誉

2004年 上海市科技进步奖一等奖

2004年 上海市医学科技奖三等奖

2006年 上海市科技进步奖二等奖

2006年 上海市医学科技奖三等奖

2006年 上海市优秀发明选拔赛一等奖

2007年 上海市职工科技创新成果奖二等奖

2008年 明治乳业生命科学奖科学奖

2006年 享受国务院特殊津贴

2009年 新世纪百千万人才工程国家级人选

2009年 上海市优秀学科带头人(A类)

2009年 上海领军人才

2014年 上海市科技进步二等奖

 

代表性论文

  1. Tao Fang, Meiling Cui, Ji Sun, Chao Ge, Fangyu Zhao, Lin Zhang, Hua Tian, Lixing Zhang, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Ming Yao, Hong Li#, Jinjun Li#. Orosomucoid 2 inhibits tumor metastasis and is upregulated by CCAAT/enhancer binding protein β in hepatocellular carcinomas. Oncotarget,  in press 2015

  2. Lin Zhang*, Hong Li*, Chao Ge, Meng Li, Fang-yu Zhao, He-lei Hou, Miao-xin Zhu, Hua Tian, Li-xing Zhang, Tao-yang Chen, Guo-ping Jiang, Hai-yang Xie, Ying Cui, Ming Yao and Jin-jun Li#. Inhibitory effects of transcription factor Ikaros on the expression of liver cancer stem cell marker CD133 in hepatocellular carcinoma. Oncotarget,  5(21) (2014) 10621-10635

  3. Hua Tian, Chao Ge, Hong Li, Fangyu Zhao, Helei Hou, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Ming Yao, Jinjun Li#. RRM2B inhibits cell migration and spreading by Egr-1-mediated PTEN/Akt1 pathway in hepatocellular carcinoma. Hepatology, 59(4) (2014) 1459-1470 

  4. Helei Hou, Hefen Sun, Ping Lu, Chao Ge, Lixing Zhang, Hong Li, Fangyu Zhao, Hua Tian, Lin Zhang, Taoyang Chen, Ming Yao, Jinjun Li#. Tunicamycin potentiates cisplatin anticancer efficacy through the DPAGT1/Akt/ABCG2 pathway in mouse xenograft models of human hepatocellular carcinoma. Mol Cancer Therap, 12(12) (2013) 2874-2884

  5. Mingxia Yan, Hong Li, Miaoxin Zhu, Fangyu Zhao, Lixing Zhang, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Ming Yao, Jinjun Li#.G Protein-Coupled Receptor 87 (GPR87) Promotes the Growth and Metastasis of CD133+ Cancer Stem-like Cells in Hepatocellular Carcinoma. PLoSONE,  8(4) ( 2013) e61056

  6. Lixing Zhang, Hefen Sun, Fangyu Zhao, Ping Lu, Chao Ge, Hong Li, Helei Hou, Mingxia Yan, Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Xiaowu Huang, Jia Fan, Ming Yao, Jinjun Li#. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocelluar carcinoma. Cancer Res, 72(16) (2012)  4276-4285

  7. Hefen Sun, Helei Hou, Ping Lu, Lixing Zhang, Fangyu Zhao, Chao Ge, Tingpu Wang, Ming Yao, Jinjun Li#. Isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis. PLoS ONE, 7(5) (2012) e36808

  8. Hong Li, Chao Ge, Fangyu Zhao, Mingxia Yan, Chen Hu, Deshui Jia, Hua Tian, Miaoxin Zhu,Taoyang Chen, Guoping Jiang, Haiyang Xie, Ying Cui, Jianren Gu, Hong Tu, Xianghuo He, Ming Yao, Yongzhong Liu, Jinjun Li#. HIF-1α-activated ANGPTL4 contributes to tumor metastasis via VCAM-1/integrin β1 signaling in human hepatocellular carcinoma. Hepatology, 54(3) (2011) 910-919

  9. Zheng Zhu*, Xiangfang Hao*, Mingxia Yan, Ming Yao, Chao Ge, Jianren Gu, Jinjun Li#. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer, 126(9) (2010) 2067-2078

  10. Chen Hu*, Hong Li*, Jin-Jun Li#, Zheng Zhu, Sheng-Yong Yin, Xiang-Fang Hao, Ming Yao, Shu-Sen Zheng, Jian-Ren Gu. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis, 29(12) (2008) 2289-2297

  11. Yin S*, Li J*, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang S, Zheng S#, Gu J#. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer, 120(7) (2007) 1444-1450

  12. Wan D*, Gong Y*, Qin W*, Zhang P*, Li J*, Wei L*, Zhou X, Li H, Qiu X, Zhong F, He L, Yu J, Yao G, Jiang H, Qian L, Yu Y, Shu H, Chen X, Xu H, Guo M, Pan Z, Chen Y, Ge C, Yang S#, Gu J#. Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc Natl Acad Sci USA, 101(44) (2004) 15724-15729

 

发明专利

已申报14项国家发明专利,其中8项已获授权

 

李宗海,博士,研究员,博士生导师,PI
Emailzonghaili@shsci.org
Tel021-64436601 
Fax021-64432027

                                

研究方向:抗体药物、细胞治疗药物、肿瘤纳米药物、肿瘤新靶点研究

联系方式:通讯地址:上海市斜土路2000弄25号

          邮政编码:200032

          邮箱:zonghaili@shsmu.edu.cn; zonghaili@shsci.org

个人简介:

医学博士、研究员,上海交通大学肿瘤研究所癌基因及相关基因国家重点实验室研究组长,国际药物创新联盟执行理事、美国癌症协会会员、美国基因治疗协会会员、中国医药生物技术协会基因治疗分会委员。他长期致力于研制高效安全的抗肿瘤生物药物(主要为抗体药物、靶向给药系统及免疫细胞治疗)和开发肿瘤新治疗靶标。他承担国家新药创制科技重大专项,传染病重大专项,973,国家自然科学基金面上项目,上海市科委重点科技攻关及企业合作项目等十余项课题。已发表论文六十余篇,其中作为通讯作者在CANCER RESEARCH, BIOMATERIALS, CELL DEATH & DISEASE, FASEB J, JBC, NEOPLASIA, CARCINOGENESIS, MOL CANCER, CANCER IMMUNOL IMMUNOTHER发表SCI收录论文近二十五篇,参编专著2部,申报发明专利二十余项,获得中国、美国、欧盟授权发明专利10项,其中有6件专利完成转化。他曾获得教育部新世纪优秀人才、上海市青年科技启明星、上海卫生系统优秀学科带头人等称号。

 

十篇代表性论著:

  1. Zhou M, Wang H, Zhou K, Luo X, Pan X, Shi B, Jiang H, Zhang J, Li K, Wang HM, Gao H, Lu S, Yao M, Mao Y, Wang HY, Yang S, Gu J, Li C, Li Z#. A Novel EGFR Isoform Confers Increased Invasiveness to Cancer Cells. Cancer Res. 2013, 73(23):7056-67.

  2. Pengnan Zhang*, Pengfei Zhang*, Bizhi Shi, Hua Jiang, Haiyan Zhang, Min Zhou, Xiaorong Pan, Huiping Gao, Hong Sun# and Zonghai Li#, Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Cell Death & Disease, 5:e991, 2014

  3. Jiang Hua*, Qiongna Dong*, Xiaoying Luo, Bizhi Shi, Huamao Wang, Huiping Gao, Juan Kong, Jiqin Zhang, Zonghai Li#, The Monoclonal Antibody CH12 augments 5-fluorouracil-induced Growth Suppression of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III, Cancer Letter, 2014;342(1):113-20.

  4. Zhang P, Shi B, Gao H, Jiang H, Kong J, Yan J, Pan X, Li K, Zhang P, Yao M, Yang S, Gu J, Wang H, Li Z#. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression. Cancer Immunol Immunother. 2014 Feb;63(2):121-32

  5. Zhang P, Zhang P, Zhou M, Jiang H, Zhang H, Shi B, Pan X, Gao H, Sun H, Li Z#. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer. Carcinogenesis. 2013; 34(11):2639-46.

  6. Yaqiong Yang, Hua Jiang, Huiping Gao, Juan Kong, Pengwei Zhang, Suwen Hu, Bizhi Shi, Pengfei Zhang, Ming Yao, Zonghai Li#. The Monoclonal Antibody CH12 Enhances the Sorafenib-Mediated Growth Inhibition of Hepatocellular Carcinoma Xenografts Expressing Epidermal Growth Factor Receptor Variant III. Neoplasia. 2012, 14(6), 509-18

  7. Wang JL, Tang GP, Shen J, Hu QL, Xu FJ#, Wang QQ, Li ZH#, Yang WT. A gene nanocomplex conjugated with monoclonal antibodies for targeted therapy of hepatocellular carcinoma.  Biomaterials. 2012;33(18):4597-607.

  8. Hai Wang, Bizhi Shi, Qingli Zhang, Hua Jiang, Suwen Hu, Juan Kong, Ming Yao, Shengli Yang, Zonghai Li# Growth and Metastasis Suppression of Glioma Xenografts Expressing Exon 4-deletion Variant of Epidermal Growth Factor Receptor by Monoclonal Antibody CH12–Mediated Receptor Degradation. FASEB J. 2012; 26(1): 73-80

  9. Hua Jiang, Huamao Wang, Zhonghua Tan, Suwen Hu, Hai Wang, Bizhi Shi, Lin Yang, Peiyong Li, Jianren Gu, Hongyang Wang, Zonghai Li#. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III. J Biol Chem. 2011;286(7):5913-20.

  10. Hai Wang*, Min Zhou*, Bizhi Shi, Qingli Zhang, Hua Jiang, Yinghao Sun, Jianhua Liu, Keke Zhou, Ming Yao, Jianren Gu, Shengli Yang,Ying Mao, Zonghai Li#. Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia, 2011,13(5):461-71

 

 

 

 

 

刘永忠 博士,研究员,博士生导师

癌基因及相关基因国家重点实验室,肿瘤免疫调节研究组

上海交通大学医学院仁济医院,上海市肿瘤研究所

电话:86-21-34206283;86-21-34206043

传真:86-21-34206283

电邮:liuyzgshsci.org

地址:上海市东川路800号上海交通大学,文选医学楼440室

邮编:200240

 

  刘永忠博士2003年获复旦大学博士学位。2003至2008年先后在美国Roswell Park肿瘤研究所和美国国立卫生研究院(NIH)进行博士后研究。2008年进入上海交通大学,上海市肿瘤研究所,癌基因及相关基因国家重点实验室工作,现为研究员,肿瘤免疫调节组研究组组长,上海交通大学医学院博士生导师。主持和参加国家自然基金、浦江人才基金、上海市人才发展计划和国家十二五重大专项等多项科研项目。曾在Nature Immunology, Hepatology, Carcinogenesis等杂志发表多篇研究论文。

 

研究方向

  1. 肿瘤免疫耐受机制和调控

2)  细胞转化和恶变的分子机制

 

研究介绍

肿瘤和间质细胞间动态的相互作用决定肿瘤的发生和发展。 肿瘤细胞和免疫系统的对话所形成的炎性或免疫状态呈负性的微环境格局,调控肿瘤的转移和进展。研究肿瘤细胞和免疫系统相互作用的分子机制不仅有助于认识肿瘤进展的机制,也将为肿瘤治疗提供新策略。本研究组利用基因敲除鼠、分子生物学和免疫学技术,主要开展以下研究工作:1)肿瘤和间质细胞间相互作用的分子机制;2)免疫抑制性细胞发育和功能,特别是关于调节性T细胞的研究;3)细胞分化、转化和癌变的分子机制。

 

代表性论

  1. Zhang L, Yang Z, Ma A, Qu Y, Xia S, Xu D, Ge C, Qiu B, Xia Q, Li J, Liu Y*. Growth arrest and DNA damage 45G down-regulation contributes to Janus kinase/signal transducer and activator of transcription 3 activation and cellular senescence evasion in hepatocellular carcinoma. Hepatology. 2014 Jan;59(1):178-89.

  2. Liu Y, Xu Y, Sun J, Ma A, Zhang F, Xia S, Xu G, Liu Y*. AKT hyperactivation confers a Th1 phenotype in thymic Treg cells deficient in TGF-β receptor II signaling. Eur J Immunol. 2014 Feb;44(2):521-32.

  3. Liu L#, Yang Z#, Xu Y, Li J, Xu D, Zhang L, Sun J, Xia S, Zou F, Liu Y*. Inhibition of oxidative stress-elicited AKT activation facilitates PPARγ agonist-mediated inhibition of stem cell character and tumor growth of liver cancer cells. PLoS One. 2013 Aug 30;8(8):e73038.

  4. Qu Y, Zhang L, Ma A, Zhang F, Li J, Xu D, Yang Z, Qin W, Liu Y*. c-MYC overexpression overrides TAK1 dependency in efficient tumorigenicity of AKT-transformed cells. Cancer Lett. 2013 Aug 19;336(2):290-8.

  5. Li J#, Liu Y#, Wang B, Xu Y, Ma A, Zhang F, Ge C, Yang Z, Li J, Liu Y*. Myeloid TGF-β signaling contributes to colitis-associated tumorigenesis in mice. Carcinogenesis. 2013 Sep;34(9):2099-108.

  6. Yang Z, Zhang L, Ma A, Liu L, Li J, Gu J, Liu Y*. Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One. 2011;6(12):e28405.

  7. Liu Y, Zhang P, Li, J, Perruche S, Kulkarni A, Chen WJ. A critical function for TGF-β signaling in the development of nature regulatory T cells.  Nature Immunology. 2008, 9, 632 – 640.


 

 

 

覃文新,研究员、医学科学博士、博士生导师

地址:上海市斜土路2200弄25号上海市肿瘤研究所新楼501(办)、503(实)

邮编:200032

电话:021-64436581(办),021-64436572(实)

传真:021-64432142

电子邮件:wxqin@sjtu.edu.cn  

 

覃文新 出生于湖南省桃源县,医学科学博士,上海市肿瘤研究所癌基因及相关基因国家重点实验室研究员、博士生导师。1985年毕业于武汉大学生物系,获理学学士学位,1998年在上海医科大学获医学科学博士学位,2007至2008年在美国系统生物学研究所(Institute for Systems Biology)从事访问研究。现任上海市肿瘤研究所“癌基因及相关基因国家重点实验室”研究组长、国际癌症质子动力学协会(ISPDC)会员、中国蛋白质组委员会委员、上海市遗传学会理事。入选上海领军人才和上海市优秀学科带头人计划,享受国务院政府特殊津贴。

主要从事肿瘤标志物与肿瘤早期诊断、肿瘤微环境、肿瘤转移研究。在肿瘤标志物与肿瘤早期诊断研究领域,首次发现分泌蛋白DKK1在人类肿瘤中高表达,并证明DKK1可作为新的肿瘤血液蛋白标志物,用于人类恶性肿瘤的早期诊断和预后判断,论文在《柳叶刀肿瘤学(The Lancet Oncology)》发表,并获美国专利2项、中国专利1项。在肿瘤微环境与肿瘤转移及耐药研究方面,研究并发现质子泵形成的肿瘤酸性微环境促进肿瘤转移和耐药的分子机制,开辟了肿瘤微环境研究的新领域。

曾主持国家863课题1项、国家973课题2项、国家重大科技专项课题1项、国家自然科学基金课题1项等多项国家和省部级课题。现主持国家重大科技专项课题1项、国家卫生行业专项课题1项、国家自然科学基金课题1项等。研究成果以通信作者或第一作者在The Lancet Oncology《柳叶刀肿瘤学》、PNAS《美国国家科学院学报》、Cancer Research《癌症研究》、Oncogene《癌基因》等国际科学期刊发表,出版《肿瘤微环境》学术译著1部。

 

五篇代表性论文 (*通讯作者)

1.   Fan S, Niu Y, Tan N, Wu Z, Wang Y, You H, Ke R, Song J, Shen Q, Wang W, Yao G, Shu H, Lin H, Yao M, Zhang Z, Gu J, Qin W*. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump. Oncogene. 2013 Mar 28;32(13):1682-90.

2.   Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W*. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012 Aug;13(8):817-26.

3.   Sheng SL, Huang G*, Yu B, Qin WX*. Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem. 2009 Sep;55(9):1656-64.

4.   Yu B, Yang X, Xu Y, Yao G, Shu H, Lin B, Hood L, Wang H, Yang S, Gu J, Fan J*, Qin W*. Elevated expression of DKK1 is associated with cytoplasmic/nuclear beta-catenin accumulation and poor prognosis in hepatocellular carcinomas. J Hepatol. 2009 May;50(5):948-57.

5.   Lu X, Qin W*, Li J, Tan N, Pan D, Zhang H, Xie L, Yao G, Shu H, Yao M, Wan D, Gu J, Yang S. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res. 2005 Aug 1;65(15):6843-9.

 

特邀通讯和综述(*通讯作者)

1. Shen Q, Wang N, Yang X-R, Zhao W, Qin W*. Dickkopf -1 and hepatocellular carcinoma-Authors' reply. Lancet Oncol. 2012 Oct, 13(10): e410 (Correspondence).

2. Fais S, De Milito A, You H, Qin W*. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res. 2007 Nov 15;67(22):10627-30 (Review).

 

 

屠红,医学博士,研究员,博士生导师
地址:上海市斜土路2200弄25号上海市肿瘤研究所老大楼310、315室
邮编:200032
电话:21-64437301;21-64437196
传真:21-64437196 
E-mail: tuhong@shsci.org

 

个人经历

1990年毕业于上海医科大学(现复旦大学上海医学院)临床医学专业。1990年至1996年间在上海医科大学基础部微生物学教研室担任助教和讲师。1994年起进入上海医科大学基础医学院“分子病毒卫生部重点实验室”读研究生,1997年赴美国南加州大学医学院微生物与免疫学专业进行博士联合培养,1999年获博士学位。1999年至2001年在法国巴斯德研究所INSERM U370从事博士后研究工作。2002年1月回国,历任上海市肿瘤研究所副研究员、研究员、博士生导师,2008年起受聘为“癌基因及相关基因国家重点实验室”课题组长。2005至2009年期间,兼任美国路易斯安娜州立大学PBRC研究所Research Instructor。

 

Hong Tu, MD, Ph.D, professor of basic medical science at Stated Key Laboratory of Oncogenes and Related Genes, Shanghai Jiao-Tong University School of Medicine, Renji Hospital, Shanghai Cancer Institute, is a medically trained researcher with graduate training in molecular virology at Shanghai Medical University and the University of Southern California, and postgraduate training in cell biology at INSERM U370, Necker/Pasture institute, France. Before, she had been working as a lecture in Shanghai Medical University and a research instructor in Pennington Biomedical Research Cencer, Louisiana State University, USA.

 

研究方向和内容

  1. 肿瘤的病毒病因学研究  重点研究乙型肝炎病毒(HBV)与肝癌、胰腺癌和非霍奇金淋巴瘤的相关性及致癌机制,并以病毒为主要参数,构建有效的肿瘤预警模型,从预防和早诊早治角度,提高瘤瘤患者的生存时间和生存质量,降低肿瘤的死亡率。

  2. 肿瘤的整合生物学研究  癌是表现为局部组织细胞异常增生的系统性疾病,课题组重点探索良性精神行为对肿瘤生长转移的抑制作用,以及神经、免疫和内分泌在其中的系统调控机制。

 

  1. Viral oncology  Special interests lay on the relationships between hepatitis B virus and several types of malignant tumor such as hepatocellular carcinoma, pancreatic cancer and non-Hodgkin’s lymphoma. The viral factors involved in the development of cancer will be identified and used to construct a predictive scoring system which will be useful in cancer prevention and intervention. 

 

  1. Systemic regulation of Cancer  Cancer is systems disease characterized by abnormal cell growth in a defined tissue or organ. We focus on the impact of eustress on cancer development, and the mechanisms how peripheral cancer growth controlled by central nervous system.

 

代表性论文专著

 

Wu Y, Gan Y, Gao F, Zhao Z, Jin Y, Zhu Y, Sun Z, Wu H, Chen T, Wang J, Sun Y, Fan C, Xiang Y,Qian G, Groopman JD, Gu J, Tu H*. Novel Natural Mutations in the Hepatitis B Virus Reverse Transcriptase Domain Associated with Hepatocellular Carcinoma. PLoS One. 2014, 9(5):e94864

屠红. 乙型肝炎病毒基因异质性与肝癌风险——来自启动肝癌高发现场的现象与思考. 《微生物与感染研究荟萃》, 2014年1月,复旦大学出版社,PP87-94,主编:闻玉梅 袁正宏。

Cai X, Gan Y, Fan Y, Hu J, Jin Y, Chen F, Chen T, Sun Y, Wang J, Qin W, Tu H. The adiponectin gene single-nucleotide polymorphism rs1501299 is associated with hepatocellular carcinoma risk. Clin Transl Oncol. 2014, 16(2):166-72

Jin Y, Gao H, Chen H, Wang J, Chen M, Li G, Wang L, Gu J, Tu H. Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent non-cancerous tissues. Cancer Lett. 2013, 28;335(2):447-54.

Chen M, Li G, Yan J, Lu X, Cui J, Ni Z, Cheng W, Qian G, Zhang J, Tu H. Reevaluation of glypican-3 as a serological marker for hepatocellular carcinoma. Clin Chim Acta. 2013, 23;423:105-11

Hong Tu. Leptin, Adiponectin and Cancer. Handbook of Biologically Active Peptides (2nd edition). P524-530, Edited by Abba Kastin Published: FEB-2013, ISBN: 9780123850959, Imprint: ACADEMIC PRESS Copyright © 2013 Elsevier Inc

Bai X, Zhu Y, Jin Y, Guo X, Qian G, Chen T, Zhang J, Wang J, Groopman JD, Gu J, Tu H. Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high-risk for hepatocellular carcinoma  Carcinogenesis, 2011, 32(1):63-8.

Zhu Y, Jin Y, Guo X, Bai X, Chen T, Wang J, Qian G, Groopman JD, Gu J, Li J, Tu H. Comparison study of complete sequences of hepatitis B virus identifies new mutations in core gene associated with hepatocellular carcinoma.  Cancer Epidemiol Biomarkers Prev,2010, 19(10):2623-30.

Tu H, Hsuchou H, Kastin AJ, Wu X, Pan W. Unique leptin trafficking by a tailless receptor. FASEB J, 2010 24(7):2281-91

Guo X, Jin Y, Qian G, Tu H.  Sequential accumulation of the mutations in core promoter of hepatitis B virus is associated with the development of hepatocellular carcinoma in Qidong, China . J Hepatol, 2008, 49(5):718-25

Tu H, Kastin AJ, Hsuchou H, Pan W. Soluble receptor inhibits leptin transport. J Cell Physiol. 2008, 214(2):301-305

Tu H, Kastin AJ, and Pan W. Corticotropin-releasing hormone receptor (CRHR)1 and CRHR2 are both trafficking and signaling receptors for urocortin. Mol Endocrinol, 2007, 21(3):700-711

Tu H, Pan W, Fencht L, Kastin AJ. Convergent trafficking pattern of leptin after endocytosis mediated by ObRa-ObRd. J Cell Physiol, 2007, 212(1):215-222

 

 

姚明,博士,研究员

地址:上海市斜土路2200弄25号

邮编:200032

电话:86-21-64183618

E-mail:myao@shsci.org

 

姚明,博士,上海交通大学医学院附属仁济医院,上海市肿瘤研究所,癌基因和相关基因国家重点实验室研究员,实验病理学课题组长(PI),国家自然科学基金项目,国家科学技术奖及上海市科委等多个基金的评审专家。担任《实验动物与比较医学》杂志副主编,《肿瘤》杂志编委,上海市实验动物学会副理事长,上海市医学会肿瘤靶分子专业委员会委员等职务。目前主持国家自然科学基金、上海市科委科技创新行动计划等项目,参与国家科技重大专项、科技部“973"等各类课题多项。建立了肺癌,肝癌,肠癌,乳腺癌,卵巢癌等各类常见肿瘤动物模型;建立了小动物分子影像学平台,蛋白组学质谱分析平台,自动化病理检测平台等多个高端技术平台。近年来主要从事肺癌转移动物模型的建立及肿瘤转移的分子机制研究,相关的工作已申请发明专利6项(授权2项),作为共同主编编写《人类疾病动物模型复制方法学》《实验动物学教程》等专箸,主持或主要参与的多个项目获得上海市医学科技二等奖、国家教育部自然科学奖二等奖等8项成果。发表各类论文80余篇,其中第一作者和通讯作者发表论文20余篇,主要工作发表在Oncogene,Journal of Proteome Research,Molecular Cancer, 等国际主流杂志。

 

代表性论文

[1]T Yu, J Li, M Yan, L Liu, H Lin, F Zhao, L Sun, Y Zhang, Y Cui, F Zhang, J Li, X He,  M Yao*(通讯作者) MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene, 34:413-423, 2015

[2]Jing Li, Qiang Tan, Mingxia Yan, Lei Liu, Hechun Lin, Fangyu Zhao, Guoliang Bao, Hanwei Kong,Chao Ge, Fanglin Zhang, Tao Yu, Jinjun Li, Xianghuo He, Ming Yao* (通讯作者)miRNA-200c inhibits invasion and metastasis of human non-small cell lung cancer by directly targeting ubiquitin specific peptidase 25, Molecular Cancer, 13(166):1-14,2014

[3] Fanglin Zhang, Hechun Lin, Aiqin Gu, Jing Li, Lei Liu, Tao Yu, Yongqi Cui,Wei Deng, Mingxia Yan, Jinjun Li, Yao Ming*(通讯作者) SWATHTM- and iTRAQ-based quantitative proteomic analyses reveal an overexpression and biological relevance of CD109 in advanced NSCLC. Journal of Proteomics  102C: 125-136,2014

[4]Lin He-chun, Zhang Fang-lin, Geng Qin, Yu Tao, Cui Yong-qi, Liu  Xiao-hui, Li Jing, Yan Ming-xia, Liu Lei, He Xiang-huo, Li Jin-jun, Yao Ming*(通讯作者)Quantitative Proteomic Analysis Identifies USP25 as a Novel Metastasis-promoting Gene in NSCLC. Journal of Proteome Research, 12(7), pp 3423-3433, 2013

[4]  Wang Xiao-Min, Li Jing, Yan Ming-Xia, Liu Lei, Jia De-Shui, Geng Qin, Lin He-Chun, He Xiang-Huo, Li Jin-Jun, Yao Ming*(通讯作者). Integrative Analyses Identify Osteopontin, LAMB3 and ITGB1 as Critical Pro-Metastatic Genes for Lung Cancer. PLos One, 8(2), e55714, 2013

  

 

张志刚,博士
地址:上海市闵行区东川路800号文选医学楼428室(办)、407室(实)
邮编:200240
电话:021-34206763(办),021-34206022(实)
传真:021-34206763
电子邮件:zzhang@shsci.org

张志刚,研究组长,2003年毕业于中科院遗传与发育生物学研究所,获博士学位。2003年至2009年在德国科隆大学生物化学研究所作为博士后,主要参与了细胞微环境(细胞外基质蛋白)以及肿瘤学方面的研究。2009年10月张志刚博士以人才引进方式来上海市肿瘤研究所癌基因及相关基因国家重点实验室工作,现任神经递质与肿瘤微环境研究组组长。国际细胞外基质生物学会成员,中国细胞外基质学会发起人之一(共有5名发起人),中国老年学协会衰老与抗衰老科学委员会理事,中国遗传学会终身会员。担任第九届泛太平洋地区结缔组织国际会议主席之一。担任多个SCI杂志的审稿人,包括Psychoneuroendocrinology(IF:5.137),Plos One等多个国际杂志。已获得国家重大研究计划、国家自然科学基金面上项目、十二五国家重大专项、国家高技术研究发展计划(863计划)、上海市教委科研创新项目、上海交通大学“医工交叉研究基金”等课题资助。已发表SCI论文40多篇,申请国家发明专利8项,获国家专利授权3项,申请国际PCT专利1项, 参与编写中英文专著2本。

 

3年发表的主要论著(selected)

  1. Li J, Yang XM, Wang YH, Feng MX, Liu XJ, Zhang YL, Huang S, Wu Z, Xue F, Qin WX, Gu JR, Xia Q, Zhang ZG*. Monoamine oxidase A suppresses Hepatocellular Carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling. Journal of Hepatology, 2014 Jun;60(6):1225-34. doi: 10.1016/j.jhep.2014.02.025. Epub 2014 Mar 6. (*Corresponding author,  IF=10.401)

  2. Wen SY, Lin Y, Yu YQ, Cao SJ, Zhang R, Yang XM, Li J, Zhang YL, Wang YH, Ma MZ, Sun WW, Lou XL, Wang JH, Teng YC, Zhang ZG*. miR-506 acts as a tumor suppressor by directly targeting the Hedgehog pathway transcription factor Gli3 in human cervical cancer. Oncogene, 2014 Mar 10. doi: 10.1038/onc.2014.9. [Epub ahead of print] (*Corresponding author,  IF=8.559

  3. Ma MZ, Zhuang C, Yang XM, Zhang ZZ, Ma H, Zhang WM, You HY, Qin W, Gu J, Yang S, Cao H, Zhang ZG*. CTHRC1 acts as a prognostic factor and promotes invasiveness of gastrointestinal stromal tumors by activating Wnt/PCP-Rho signaling. Neoplasia, 2014 Mar; 16(3):265-278.e13. doi: 10.1016/j.neo.2014.03.001. Epub 2014 Apr 13. (*Corresponding author,  IF=5.398

  4. Fu Y, Feng MX, Yu J, Ma MZ, Liu XJ, Li J, Yang XM, Wang YH, Zhang YL, Ao JP, Xue F, Qin W, Gu J, Xia Q and Zhang ZG*. DNA methylation-mediated silencing of matricellular protein dermatopontin promotes hepatocellular carcinoma metastasis by α3β1 integrin-Rho GTPase signaling. Oncotarget, 2014, July 21. Advance publications (*Corresponding author,  IF=6.627

  5. Liu XJ, Xu MJ, Fan ST, Wu Z, Li J, Yang XM, Wang YH, Xu J and Zhang ZG*. Xiamenmycin attenuates hypertrophic scars by suppressing local inflammation and the effects of mechanical stress. J Invest Dermatol. 2013 May;133(5):1351-60. doi: 10.1038/jid.2012.486. Epub 2013 Jan 10. (*Corresponding author,  IF=6.372)

  6. Liu XJ, Kong FZ, Wang YH, Zheng JH, Wan WD, Deng CL, Mao GY, Li J, Yang XM, Zhang YL, Zhang XL, Yang SL, Zhang ZG*. Lumican Accelerates Wound Healing by Enhancing α2β1 Integrin-Mediated Fibroblast Contractility. PLoS One. 2013 Jun 26;8(6):e67124. Print 2013. (*Corresponding author,  IF=3.534

  7. Lin L, Yang XM, Li J, Zhang YL, Qin W, Zhang ZG*. Microfilament regulatory protein MENA increases activity of RhoA and promotes metastasis of hepatocellular carcinoma. Exp Cell Res. 2014 May 22. pii: S0014-4827(14)00201-8. doi: 10.1016/j.yexcr.2014.05.010. [Epub ahead of print] (*Corresponding author,  IF=3.372

  8. Xu MJ, Liu XJ, Zhao YL, Liu D, Xu ZH, Lang XM, Ao P, Lin WH, Yang SL, Zhang ZG*, Xu J. Identification and Characterization of an Anti-Fibrotic Benzopyran Compound Isolated from Mangrove-Derived Streptomyces xiamenensis. Mar Drugs. 2012 March; 10(3): 639–654. (*Co-corresponding author,  IF=3.978

  9. Wen SY, Zhang LN, Yang XM, Zhang YL, Ma L, Ge QL, Jiang SH, Zhu XL, Xu W, Ding WJ, Yang BQ, Zhang ZG*, Teng YC. LRG1 is an independent prognostic factor for endometrial carcinoma. Tumor Biol. 2014 Jul;35(7):7125-33. (*Co-corresponding author,  IF=2.84

  10. Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, Cao H, Zhang ZG*. Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome. BMC Gastroenterol. 2014 Jun 7;14:105. (*Corresponding author, IF=2.113

  11. Wu Z, Wu Z, Li J, Yang X, Wang Y, Yu Y, Ye J, Xu C, Qin W, Zhang Z*. MCAM is a novel metastasis marker and regulates spreading, apoptosis and invasion of ovarian cancer cells. Tumor Biol. 2012 Oct;33(5):1619-1628 (*Corresponding author, IF=2.52

  12. Dou XQ, Yang XM, Li P, Zhang ZG*, Schönherr H, Zhang D, Feng CL. Novel pH Responsive Hydrogels for Controlled Cell Adhesion and Triggered Surface Detachment. Soft Matter, 2012,8, 9539-9544 (*Co-corresponding author, IF=3.909

  13. Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, Wang N, Niu Y, Wu Z, Zhou J, Qiu SJ, Shi YH, Yu B, Tang N, Chu W, Wang M, Wu J, Zhang Z, Yang S, Gu J, Wang H, Qin W. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012 Aug;13(8):817-26. (IF: 25.117)

  14. Fan S, Niu Y, Tan N, Wu Z, Wang Y, You H, Ke R, Song J, Shen Q, Wang W, Yao G, Shu H, Lin H, Yao M, Zhang Z, Gu J, Qin W. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump. Oncogene. 2013 Mar 28;32(13):1682-90. doi: 10.1038/onc.2012.183. Epub 2012 May 14. (IF: 8.559)

 

 

 

庄光磊,博士,研究员,博导

上海交通大学,医学院-仁济医院,癌基因及相关基因国家重点实验室

 

教育经历(按时间倒排序):

2004/8 -2010/3,美国范德堡大学,癌症生物学,博士,导师:Jin Chen

2000/8 -2004/6,北京大学,生命科学,学士,导师:王忆平

 

工作经历(科研与学术工作经历,按时间倒序排序):

2014/8 -至今,上海交通大学,医学院附属仁济医院,临床干细胞研究中心,癌基因及相关基因国家重点实验室,研究员

2010/4 – 2014/7,美国基因泰克公司,研发部,博士后,导师:NapoleoneFerrara, M.D.(美国科学院院士,2010年拉斯科奖)

 

主持或参加科研项目及人才计划项目情况(按时间倒序排序):

1、国家自然科学基金面上项目,81472537,特异micoRNAs与Lin28B的相互调控促进黑色素瘤发展的机制研究,2015年1月至2018年12月,78万,在研,主持。

2、上海高校特聘教授(东方学者),2015年6月至2018年5月,100万,在研,主持。

3、美国国防部乳腺癌项目博士研究基金, BC073186,Role of EphA2receptor in HER2 signaling and drug resistance in breast cancer,2008年1月至2010年12月,10万美元,已结题,主持。

 

主要研究领域

Omics data-mining and functional characterization of molecular cancer targets.Tumor stroma and intratumor heterogeneity.Translational research and precision medicine in lung and ovarian cancer.

 

代表性论文

8.Li X., Liu Y., Chen W., Fang Y., Xu H., Zhu H.H., Chu M., Li W., Zhuang G.*, and Gao W.Q*. TOP2Ahigh is the phenotype of recurrence and metastasis whereas TOP2Aneg cells represent cancer stem cells in prostate cancer. Oncotarget. 2014 Oct 15; 5(19):9498-513. *co-corresponding authors

7.      Brauer M.J. *, Zhuang G. *, Schmidt M. *, Yao J., Wu X., Kaminker J.S., Jurinka S.S., Kolumam G., Chung A.S., Jubb A., Modrusan Z., Ozawa T., James C.D., Phillips H., Haley B., Tam R.N., Clermont A.C., Cheng J.H., Yang S.X., Swain S.M., Chen D., Scherer S.J., Koeppen H., Yeh R.F., Yue P., Stephan J.P., Hedge P., Ferrara N., Singh M. *, and Bais C*. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res. 2013 Jul 1; 19(13):3681-92. *equal contribution

6.      Zhuang G. *, Yu K. *, Jiang Z., Chung A.S., Yao J., Ha C., Toy K., Soriano R., Haley B., Blackwood E., Sampath D., Bais C., Lill J.R., and Ferrara N. Phosphoproteomic analysis implicates the mTORC2-FoxO1 axis in VEGF signaling and feedback activation of receptor tyrosine kinases. Science Signaling. 2013 Apr 16; 6(271):ra25. *equal contribution #Cover Article; featured by Science Signaling Podcast.

5. Zhuang G., Wu X., Jiang Z., Kasman I., Yao J., Qu X., Guan Y., Oeh J., Modrusan Z., Bais C., Sampath D., and Ferrara N. Tumor-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012 Jul 6; 31(17):3513-23. #Highlighted by EBMO J; Nature Reviews Cancer; Science Signaling.

4.      Zhuang G. *, Song W. *, Amato K., Hwang Y., Lee K., Boothby M., Ye F., Guo Y., Shyr Y., Lin L., Carbone D.P., Brantley-Sieders D.M., and Chen J. Effects of cancer-associated EPHA3 mutations on lung cancer. J Natl Cancer Inst. 2012 Aug 8; 104(15):1183-98. *equal contribution #Highlighted by NCI News

3.      Zhuang G., Brantley-Sieders D.M., Vaught D., Yu J., Xie L., Wells S., Jackson D., Muraoka-cook R.S., Arteaga C.L., and Chen J. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 2010 Jan 1; 70(1):299-308.

2.      Brantley-Sieders D.M.*, Zhuang G.*, Hicks D., Fang W.B., Hwang Y., Cates J.M., Coffman K., Jackson D., Bruckheimer E., Muraoka-Cook R.S., and Chen J. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2008 Jan; 118(1):64-78. *equal contribution

1.    Zhuang G., Hunter S.G., Hwang Y., and Chen J. Regulation of EphA2 receptor endocytosis by SHIP2 lipid phosphatase via phosphatidylinositol 3-Kinase-dependent Rac1 activation. J Biol Chem. 2007 Jan 26; 282(4):2683-94.

 


版权所有Copyright@2016上海交通大学生物医学工程学院    地址:上海市徐汇区华山路1954号    沪交ICP备05227